Custom service
De novo Peptide Design
Design peptide sequences de novo against a functional objective
The service is built around structure- and AI-informed sequence design. Depending on the molecule we may move to stability and solubility optimization or design-build-test iteration to improve stability, loading or yield, and every batch is released with design dossier plus synthesized candidates.
Because De novo Peptide Design projects usually feed a downstream assay or preclinical study, we lock the release specification early — purity, identity and functional readouts are agreed at quotation, not discovered at delivery.
Binders for targets without known motifs
Novel scaffolds for research programmes
Designs without a testable assay or structure
Sequences where a recombinant expression route is objectively cheaper and faster
Release specification is fixed at quotation: standard >95% by HPLC, >98% for assay-critical material. Long chains (>60 residues) are additionally confirmed by MS/MS sequence coverage, and truncated-deletion species are quantified, not just summarized.
Service Highlights
- Structure- and AI-informed sequence design as the default route, with stability and solubility optimization held as a proven fallback
- Design-build-test iteration worked into the design where the application requires it
- Sequence difficulty analysis (aggregation risk, motif hazards) is done before synthesis, and the route is chosen around it
- Analytical confirmation of every intermediate before the final release
- Microwave-assisted coupling and double-coupling are applied automatically where the sequence demands them
- Design dossier plus synthesized candidates delivered with a complete conjugation or synthesis certificate
How the work runs
Sequence analysis
De novo Peptide Design is analyzed for aggregation risk, motif hazards and puri?cation difficulty before a route is quoted.
Route selection
Fmoc solid-phase, fragment ligation or hybrid solution-phase is selected and documented.
Assembly
The chain is built with structure- and AI-informed sequence design applied where the sequence demands it, with double-coupling at hazard sites.
Cleavage & crude QC
Crude material is characterized so purification targets are set on data, not hope.
Purification
RP-HPLC (and ion-exchange where needed) delivers the agreed purity; fractions are pooled on MS confirmation.
Release
Design dossier plus synthesized candidates is documented with the full analytical package and released.
Specifications & timeline
- Turnaround
- 4–8 weeks
- Typical scale
- 0.1 mg – 10 g per sequence
- Chemistry options
- structure- and AI-informed sequence design; stability and solubility optimization; design-build-test iteration
- Deliverable
- Design dossier plus synthesized candidates
- QC package
- HPLC purity, ESI/MALDI MS, MS/MS confirmation for long chains
- Shipping
- Ambient with desiccant; blue ice for modified or sensitive peptides
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.